AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03112603
Drug: mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus)
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
Trial: NCT01411124
Drug: diphenhydramine
RxNorm normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg active comparator
Trial: NCT03112603
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
Trial: NCT03112603
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
Trial: NCT03112603
Drug: Pentostatin
RxNorm normalized name: Pentostatin
DrugBank: Pentostatin (DB00552)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
Trial: NCT02985541
Drug: Levonorgestrel IUS (Mirena, BAY86-5028)
RxNorm normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levonorgestrel (LNG) intrauterine delivery system (IUS) with an initial in vitro release rate of 20 μg levonorgestrel per day.
Trial: NCT03112603
Drug: Imatinib
RxNorm normalized name: Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
Trial: NCT03112603
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
Trial: NCT00724698
Drug: Desloratadine
RxNorm normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desloratadine 5 mg once daily
Trial: NCT03006003
Drug: Raloxifene
RxNorm normalized name: Raloxifene
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Raloxifene tratment more than 4 weeks
Trial: NCT03006003
Drug: Alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronic acid 70mg with Colecalciferol 70mcg
Trial: NCT01658033
Drug: Avastin + mFOLFOX6
RxNorm normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: mFOLFOX6 regimen, repeated every 2 weeks: Oxaliplatin 85 mg/m2，ivgtt； Leucovorin 400 mg/m2,ivgtt； 5-FU 400 mg/m2，iv，and then 2400 mg/m2，civ46h；~Avastin: Avastin 5mg/kg q2w or 7.5mg/kg q3w
Trial: NCT00043979
Drug: F-18 Fluorodeoxyglucose
RxNorm normalized name: Fludeoxyglucose F-18
DrugBank: Fludeoxyglucose (18F) (DB09502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00043979
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/kg per dose orally every other day (no day 9 dose).
Trial: NCT00043979
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg/m\^2 per day continuous intravenous (IV) infusion over 24 hours daily for 4 days. Days 1, 2, 3, 4.
Trial: NCT00043979
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction - 25 mg/m\^2 per day intravenous (IV) infusion over 30 minutes daily for 3 days. Days 1, 2, 3.~Transplant - 30 mg/m\^2 per day IV infusion over 30 minutes daily for 4 days; days -6, -5, -4, -3.
Trial: NCT00043979
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transplant - 100 mg/m\^2 per day intravenous (IV) infusion over 15 minutes for 1 day; day -2.
Trial: NCT00043979
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction - 60 mg/m\^2 per day in 2-4 divided doses by mouth daily for 5 days; days 1, 2, 3, 4, 5.
Trial: NCT00043979
Drug: sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initiated on day +3. Patients \>40kg, the initial dose will be 2 mg every 24 hours orally. Patients \<40 kg, the initial dose will be 1 mg/m\^2.
Trial: NCT00043979
Drug: tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day -1 at least 24 hours before the stem cell infusion at a dose of 0.03 mg/kg/day as a continuous infusion. Twelve hours later oral dose initiated at a dose of 0.1-0.15 mg/kg/day in two divided doses every 12 hours.
Trial: NCT00043979
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction - 0.4 mg/m\^2 per day continuous intravenous (IV) infusion over 24 hours daily for 4 days; 1, 2, 3, 4.
Trial: NCT00043979
Drug: Filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02163759
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab 160 milligrams (mg) will be administered subcutaneously (SC) at Week 0; 80 mg SC at Week 2; 40 mg SC at Weeks 4, 6, and 8.
Trial: NCT02163759
Drug: Etrolizumab
RxNorm normalized name: Etrolizumab
DrugBank: Etrolizumab (DB12189)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etrolizumab 105 mg will be administered SC every 4 weeks (Q4W) up to Week 12 (at Weeks 0 \[Day 1\], 4, 8, and 12 \[clinical remitters only\]).
Trial: NCT00093626
Drug: Sorafenib Tosylate
RxNorm normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00588016
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical application of Itraconazole in Sterile Water 100 mg/1000 ml, irrigating each nostril with 20 ml of solution twice daily for 7 days.
Trial: NCT06286488
Drug: Vaxigrip
DrugBank: Haemagglutinin-strain A(H3N2) (DB15475)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evaluation of immunogenicity and tolerance of quadrivalent influenza vaccine in groups at risk of severe influenza, including obese adults, as well as in pregnant women (with assesment of antibodies in cord blood).
Trial: NCT00333437
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03556254
Drug: GGT
RxNorm normalized name: NGGT-002
DrugBank: NGGT-002 (DB17881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the absence of 23S rRNA mutation, clarithromycin based sequential therapy will be given. In the presence of 23S rRAN mutation but the absence of gyrase A mutation, levofloxacin based sequential therapy will be given. In the presence of both 23S rRNA and gyrase A mutations or if genotyping fails, bismuth quadruple therapy will be given
Trial: NCT03556254
Drug: SGT
RxNorm normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the absence of clarithromycin resistance, clarithromycin based sequential therapy will be given. In the presence of clarithromycin resistance but the absence of levofloxacin resistance, levofloxacin based sequential therapy will be given. In the presence of both clarithromycin and levofloxacin resistance or if culture fails, bismuth quadruple therapy will be given.
Trial: NCT03022526
Drug: Bupivacaine / fentaNYL
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003523
Drug: aminocamptothecin colloidal dispersion
RxNorm normalized name: amphotericin B colloidal dispersion
DrugBank: Camptothecin (DB04690)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05199103
Drug: rabbit anti-thymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 - 1.0 mg/kg of rATG (cumulative dose of 150-200 mg given intravenously in two or three divided doses, 24 hours apart) after premedication with methylprednisolone i.v. (in total dose of 375 mg), 1 mg of antihistaminic agent clemastine and 1000 mg paracetamol i.v.
Trial: NCT04721886
Drug: Perflutren Lipid Microcpheres
DrugBank: Perflutren (DB00556)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03566134
Drug: DA-8010 5mg
RxNorm normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive DA-8010 5mg orally once a day.
Trial: NCT03566134
Drug: Solifenacin 5mg
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants receive solifenacin 5 mg orally once a day.
Trial: NCT03566134
Drug: Solifenacin succinate placebo
RxNorm normalized name: Solifenacin Succinate
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants receive placebo to match solifenacin 5 mg orally once a day.
Trial: NCT04198558
Drug: MEDI0618
DrugBank: MEDI0680 (DB15768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI0618 A novel human immunoglobulin antibody
Trial: NCT03891108
Drug: BMS-986231 Formulation A
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will be administered BMS-986231 Formulation A as IV infusion for 48 hours.
Trial: NCT03891108
Drug: BMS-986231 Formulation C
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be administered BMS-986231 Formulation C as IV infusion for 48 hours.
Trial: NCT02442739
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine 0.5 mg/kg mixed with syrup will be given by mouth once a week for 12 weeks.
Trial: NCT01397214
Drug: Megace OS
RxNorm normalized name: megestrol acetate Oral Tablet [Megace]
DrugBank: Megestrol acetate (DB00351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megace oral suspension
Trial: NCT05035381
Drug: Pembrolizumab (PD-1 Inhibitor) Combined With Bevacizumab and FOLFIRI Regimen
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: MSI-H colorectal cancer, recurrence and metastasis within 1 year after surgery, or failure of first-line oxaliplatin and fluorouracil chemotherapy for advanced colorectal cancer, PD-1 inhibitors combined with bevacizumab and FOLFIRI regimen
Trial: NCT02037399
Drug: intravenous dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients were enrolled in outpatient settings after evaluating appropriate ESD indications. A single study coordinator performed a randomization process by using a table of random numbers. The patients were allocated to receive intravenous dexamethasone (0.15 mg/kg) immediately after ESD. The patients with an odd number were assigned into DEXA group, and the patients with an even number were assigned into placebo group. The syringe including dexamethasone was completely covered with a paper sticker to mask treatment assignment. The operator and assisting nurse were also blinded to the study.~At the day and next day of ESD, intravenous proton pump inhibitor was routinely administered to prevent complications including bleeding. At 3rd day of ESD, all patients started to take 40mg oral lansoprazole once a day and sucralfate suspension 3 times a day for 28 days.
Trial: NCT00380575
Drug: YM087
RxNorm normalized name: Nepadutant
DrugBank: Nepadutant (DB12538)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02037399
Drug: intravenous normal saline
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were enrolled in outpatient settings after evaluating appropriate ESD indications. A single study coordinator performed a randomization process by using a table of random numbers. The patients were allocated to receive intravenous normal saline as placebo immediately after ESD. The patients with an odd number were assigned into DEXA group, and the patients with an even number were assigned into placebo group. The syringe including placebo was completely covered with a paper sticker to mask treatment assignment. The operator and assisting nurse were also blinded to the study.~At the day and next day of ESD, intravenous proton pump inhibitor was routinely administered to prevent complications including bleeding. At 3rd day of ESD, all patients started to take 40mg oral lansoprazole once a day and sucralfate suspension 3 times a day for 28 days.
Trial: NCT03311243
Drug: Chemical plaque control
RxNorm normalized name: Plaquenil
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01860066
Drug: fluticasone/salmeterol
RxNorm normalized name: FLUTICASONE/SALMETEROL
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: fluticasone/salmeterol via inhaler twice a day
Trial: NCT02849899
Drug: Vildagliptin
RxNorm normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Galvus is prescribed as recommended by the marketing authorization. In adults, the recommended dose of Galvus is 100 mg per day (one tablet in the morning and another in the evening).~In patients with moderate or severe kidney problems, the recommended dose is 50 mg once daily (one tablet in the morning).~Patients with creatinine clearance greater than 50 ml/min the vildalgliptin dose will be 100 mg/day. For those whose clearance is less than 50 ml/min, the daily dose is 50 mg. The creatinine clearance will be measured each week.~The treatment duration will be 3 months, divided into 2 months of complete treatment and one month of cessation treatment with half dose of vildagliptin.
Trial: NCT00066859
Drug: Zoloft 50 mg
RxNorm normalized name: Zoloft 50 MG Oral Tablet
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zoloft 50 mg by mouth daily for 1 week if tolerated dose may be increased to 100 mg daily for 4 months
Trial: NCT03903406
Drug: ixazomib in combination with lenalidomide and dexamethasone
RxNorm normalized name: dexamethasone, combinations
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients with RRMM who have received at least one prior therapy will receive Ixazomib in combination with lenalidomide and dexamethasone within the routine clinical practice in accordance with prescription. Duration of therapy - until disease progression or unacceptable toxicity.
Trial: NCT04109261
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib administration in breast cancer patients included in a compassionate use programme. Patients were treated according to the standard of care
Trial: NCT04575233
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a solution of 15 ml of Ropivacaine (0.2%) is injected for the treatment of post-operative pain after minimally invasive surgery (TAP block)
Trial: NCT00811018
Drug: Sitaxsentan
RxNorm normalized name: Sitaxsentan
DrugBank: Sitaxentan (DB06268)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Sitaxsentan 100 mg tablets once daily
Trial: NCT01170169
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole Delayed Release Capsules 40 mg
Trial: NCT01170169
Drug: Prilosec
RxNorm normalized name: Prilosec
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prilosec® 40 mg of Merck \& Co.Inc.
Trial: NCT02094924
Drug: FDC of candesartan cilexetil 16 mg and HCTZ 12.5mg
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single dose of FDC tablet formulation to be taken orally
Trial: NCT00988728
Drug: SCH 900435 (Org 25935)
RxNorm normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets, containing 8 mg of active substance, two tablets (i.e. 16 mg) to be taken twice daily in the morning after breakfast and in the evening after dinner during 4 weeks.~Because of double-dummy design, subjects will be administered two tablets in the morning, and two tablets plus one capsule in the evening (in total 4 tablets with SCH 900435 plus 1 capsule with placebo per day).
Trial: NCT00988728
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral capsules containing 15 mg of active substance, one capsule to be taken once daily after dinner for four weeks.~Because of double-dummy design, subjects will be administered two tablets in the morning, and two tablets plus one capsule in the evening (in total 4 tablets with placebo plus 1 capsule with olanzapine per day).
Trial: NCT02403648
Drug: Lilly Glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02403648
Drug: Novo Glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03941288
Drug: Cannabidiol
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cannabidiol and the matching placebo solution (excipients alone) will be provided in identical 100ml amber glass bottles. At the end of the treatment period, the treatment solutions will be tapered (10% volume each day) over 10 days.~In accordance with Food and Drug Administration guidance, prior to starting treatment and at end of 1 month treatment, we shall obtain serum transaminases (alanine and aspartate) and total bilirubin levels. These tests will also be performed if patient develops clinical signs or symptoms suggestive of hepatic dysfunction (e.g., unexplained nausea, vomiting, right upper quadrant abdominal pain, fatigue, anorexia, or jaundice and/or dark urine); if such features develop the treatment will be interrupted or discontinued.
Trial: NCT00334048
Drug: Ropinirole (Requip)
RxNorm normalized name: ropinirole Extended Release Oral Tablet [Requip]
DrugBank: Ropinirole (DB00268)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 mg extended release formulation given once per day to a maximum of 4 per day
Trial: NCT00929695
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: immunosuppressive drug
Trial: NCT00929695
Drug: methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: immunosuppressive drug
Trial: NCT03950297
Drug: 609A
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 609A is a recombinant anti-PD-1 humanized IgG4 kappa antibody that targets the human PD-1
Trial: NCT03224819
Drug: Emerfetamab
RxNorm normalized name: Emerfetamab
DrugBank: Emerfetamab (DB18474)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by intravenous (IV) infusion.
Trial: NCT02131753
Drug: Cladribine s.c. injection, HCL treatment
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with hairy cell leukemia and the need for treatment are given cladribine 0.14 mg/kg for 5 consecutive days as a s. c bolus injection
Trial: NCT02015312
Drug: Epigallocatechin-3-gallate (EGCG)
RxNorm normalized name: Epigallocatechin-3-gallate
DrugBank: Epigallocatechin gallate (DB12116)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical formulation: capsules~Dose:~400 mg/d for 3 months; 800 mg/d for 3 months, 1200 mg/d for 6 months Route of administration: p.o. Treatment duration: 12 months
Trial: NCT02546388
Drug: Indium-111 Pentreotide
RxNorm normalized name: Indium-111 Pentetreotide
DrugBank: Indium (DB11659)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02546388
Drug: Gallium-68 DOTATATE
RxNorm normalized name: Gallium 68 dotatate
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00209612
Drug: Taxol
RxNorm normalized name: Taxol
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Day1,15 X mg/m2, IV (in the vein)
Trial: NCT02129699
Drug: Denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Denosumab: 120 mg, s.c. every 3-4 weeks (in cycle 1 additional dose on day 8) until unacceptable toxicity, patient refusal or patient's death (max. 4 years 3 months).
Trial: NCT03410693
Drug: Rogaratinib (BAY1163877)
RxNorm normalized name: Rogaratinib
DrugBank: Rogaratinib (DB15078)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rogaratinib administered as oral (p.o.) tablets twice daily (b.i.d.) continuously
Trial: NCT01881828
Drug: Metformin (glucophage)
RxNorm normalized name: metformin Oral Tablet [Glucophage]
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The strength of each tablet will be 500 mg. Participants will build up to a daily dose over four weeks by taking one tablet per day for 7 days, one tablet twice daily for 7 days, one tablet in morning and 2 tablets at night for 7 days, and then 2 tablets in the morning and 2 tablets at night, daily throughout the remainder of the study treatment period.